Working… Menu

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03794297
Recruitment Status : Withdrawn (Inadequate accrual rate)
First Posted : January 7, 2019
Last Update Posted : March 17, 2021
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : February 18, 2021
Actual Study Completion Date : February 18, 2021